About Proteios Technology
Founded in 2015 with an exclusive license from the University of Washington, Proteios empowers discovery and manufacturing of advanced therapy medicinal products (ATMPs) as healthcare companies shift from small molecule drugs to ATMPs. Our platform is enabling: 1) new discoveries in Preclinical Research, 2) the cost-effective manufacturing of Biopharmaceuticals, Cell Therapies, Gene Therapies, and Antibody Therapeutics, 3) and the development of novel molecular diagnostics.
Currently located within the CoMotion Incubator on the campus of the University of Washington, Proteios is in close proximity to research expertise and analytical services available within the campus. We are conveniently located in the heart of Seattle, adjacent to the Fred Hutchinson Cancer Research Center, Seattle Children’s Research Institute, Seattle Cancer Care Alliance, and UW Medicine.
At Proteios, our diverse team of scientists, researchers, and bioengineering experts share a common mission to lower the cost of healthcare and provide access of ATMPs to a global patient population. Our strategy combines world-class science, operational excellence, and a forward-looking vision to dramatically impact the lives of patients everywhere. We strive to foster and develop a unique culture centered around the idea that a great founding team plays an integral role in shaping a successful organization. Proteios respects and values the contributions of each and every team member.
Bob Snyder, Ph.D./MBA
Bob is Cofounder and Managing Director at Proteios and has over 30 years’ experience in life science research and commercialization. He has a Ph.D. in Biochemistry from the University of California, Santa Barbara and an MBA from the University of Chicago Graduate School of Business. Bob previously held executive positions with Abbott Laboratories, Merck & Co., FEI Company, and Elsevier Science.
François Baneyx, Ph.D.
François is Cofounder and Scientific Advisor at Proteios and is currently Charles W.H. Matthaei Professor of Chemical Engineering, Director of CoMotion, and Vice Provost for Innovation at the University of Washington. He has a Ph.D. in Chemical Engineering from the University of Texas and is inventor of Proteios’ scalable platform for the manipulation of biologicals.
Our Senior Team
Proteios is interested in external funding to expand new applications empowered by the Proteios Chimera Platform.
University of Washington CoMotion Innovation Gap Fund
The University of Washington provided $50K grant to de-risk the technology coming out of the lab of Prof. Baneyx.
National Science Foundation (NSF)
NSF has supported the recombinant protein and antibody purification applications with $1.175M in grants.
National Institutes of Health (NIH)
NIH has supported the cell therapy manufacturing application with $735K in grants and contracts.
May 14, 2021
Proteios Technology, Inc. is selected to participate in the National Institutes of Health (NIH) Innovation Corps (I-Corps) program to assess the market requirements of the Cell Therapy Manufacturing market. A $55K grant is provided to fund the market research.
May 14, 2021
The National Cancer Institute (NCI) contracts with Proteios Technology, Inc. to design/development a bench-scale prototype for Autologous Cell Therapy Manufacturing. The $400K SBIR Phase I contract is in response to Topic 429 – Advanced Manufacturing to Speed Availability of Emerging Autologous Cell-Based Therapies – within the NIH/CDC SBIR Solicitation PHS2021-1. Proteios will incorporate its proven multivariate cell separation technology into the prototype to provide a high-performance, cost-effective instrument for Cell Therapy Manufacturing. Upon successful completion of the Phase I contract, Proteios will be eligible for a $2M SBIR Phase II contract to build an at-scale cGMP instrument for Cell Therapy Manufacturing.
December 29, 2020
The National Science Foundation (NSF) awards a $50K Technical and Business Assistance (TABA) supplemental grant to Proteios Technology, Inc. for commercialization activities associated with their SBIR Phase II project “Removing the Purification Bottleneck in Biopharmaceutical Production.”
June 29, 2020
The National Science Foundation (NSF) awards an SBIR Phase II grant of $750K to Proteios Technology, Inc. for support of the project “Removing the Purification Bottleneck in Biopharmaceutical Production.”
February 29, 2020
Proteios Technology, Inc. is selected to participate in the National Institutes of Health (NIH) Innovation Corps (I-Corps) program to assess the market requirements of the Cell Therapy market. A $55K grant is provided to fund the market research.
November 25, 2019
Proteios Technology, Inc. is selected to participate in the National Institutes of Health (NIH) Niche Assessment Program(NAP) to help “jump start” commercialization efforts in the Cell Therapy market.
September 19, 2019
Drs. Alessio Ligabue and Shanqiao Wei join Proteios Technology, Inc. to extend the Proteios Chimera Platform for cell separation and cell therapy manufacturing.
August 26, 2019
The National Institutes of Health (NIH) awards an SBIR Phase I grant of $224K to Proteios Technology, Inc. for support of the project “Simple and Effective Method for Cell Enrichment and Cell Depletion During Cell Therapy.”
July 5, 2019
Proteios, LLC converts to a Washington C-Corp Proteios Technology, Inc.
May 24, 2018
The National Science Foundation (NSF) awards an SBIR Phase I grant of $225K to Proteios, LLC for support of the project “Removing the Purification Bottleneck in Biopharmaceutical Production.”
April 23, 2018
Proteios, LLC moves Into CoMotion Life Science incubator laboratory located on the campus of the University of Washington.
July 7, 2015
Proteios, LLC is founded by Dr. Bob Snyder and Prof. François Baneyx to commercialize the Car9 affinity tag developed in the laboratory of Prof. Baneyx at the University of Washington. Initial development efforts will be focused on recombinant protein/biopharmaceutical purification.
July 6, 2015
The research team of Prof. François Baneyx, professor and chair, Department of Chemical Engineering, University of Washington receives $50K CoMotion Innovation Fund Grant. Car9 affinity chromatography is redefining protein purification with low-cost, environmentally-friendly kits to enable Life Science researchers to quickly and easily purify recombinant proteins produced by genetic engineering. By providing $40K for scientific development and an additional $10K for business development milestones, the CoMotion Innovation Fund will enable Car9 technology to get across the gap between the products of academic research grants and the development needed to attract seed stage investment.